Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

Interim results from a Phase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly among bortezomib-naive patients. Of 14 evaluable bortezomib-naive patients, 57 percent achieved responses, including one patient with a complete response, two with very good partial responses and five with partial responses. Four additional patients achieved stable disease. Of 31 patients treated, 10 percent have received 12 cycles of treatment and have been enrolled in an extension study. Adverse events were generally mild and manageable. These data were presented by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation at Washington University School of Medicine in a poster titled "PX-171-004, a multicenter Phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update" (Abstract #8537).

Ruben Niesvizky, M.D., Associate Attending Physician, New York-Presbyterian Hospital and Associate Professor of Medicine at Weill Cornell Medical College presented preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients. The combination of carfilzomib and lenalidomide is well tolerated and encouraging response rates have been observed. Of 18 evaluable patients, 61 percent have achieved partial or minor responses, including three very good partial responses. Notably, responses occurred in the first 28-day cycle of treatment and initial responses have improved with continued therapy. A maximum-tolerated dose has not yet been established and dose-escalation continues. These data were presented today in a poster titled "PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory mul
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 Vanda Pharmaceuticals Inc. ... data today at ENDO 2013, the Endocrine Society,s ... can entrain (synchronize) both melatonin and cortisol rhythms. ... the master body clock and address the circadian ... The SET (Safety and Efficacy of Tasimelteon) and ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, ... on the company,s lead product, DNX-2401, at the Replicating ... Canada on June 18, 2013. ... leader in the field of oncolytic virus therapy, will ... I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY ...
(Date:6/17/2013)... , June 17, 2013 BioMed Realty Trust, Inc. ... of directors has declared a second quarter 2013 dividend of ... to an annualized dividend of $0.94 per common share. ... 15, 2013 to stockholders of record at the close of ... Realty Trust BioMed Realty delivers optimal real estate ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 The Elizabeth ... of State and the U.S. President’s Emergency Plan for ... and celebrate significant new milestones in the global effort ... John Kerry announced that as of June 2013, one ... PEPFAR support. Since PEPFAR’s inception in 2003, EGPAF ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 A new ... storm. The burgeoning aquaculture industry is redefining the way ... of the most acclaimed personal culinary chefs on the ... on benefits of sustainable seafood and the promising industry ... abundance these days. Many consumers strive to fully partake ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 New York ... Center to its “Best Doctors” list, up from 129 ... York City. The new issue also lists 52 additional doctors ... continues on a strategic growth trajectory. The “Best Doctors” issue, ... in the June 24 print issue and is available online ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3
... ANN ARBOR, Mich. Black people with cancer are ... die from their disease. While disparities exist for nearly ... cancers that benefit most from treatment -- suggesting that ... to a review from researchers at the University of ...
... ... bebionic hand, the first product from its new upper extremity range, bebionic. Launched at the ... distributors worldwide, at a cost of approximately 9,000 Euros, or $11,000 USD. , ... (PRWeb UK) July 1, 2010 -- RSLSteeper ...
... , THURSDAY, July 1 (HealthDay News) -- Scientists have grouped ... 77 percent accuracy whether or not a person will live ... probably could have predicted life span with even greater accuracy ... said Dr. Robert Marion, chief of genetics and development medicine ...
... , THURSDAY, July 1 (HealthDay News) -- After having sex ... in Washington state developed an illness caused by the vaccinia ... This type of viral transmission, while rare, is not unheard ... Prevention. "The patient visited an urgent care clinic with ...
... Researchers at Oregon State University and the California Institute of ... to many life functions also plays a key role in ... cell that,s important in immune function. The discovery, to ... that some types of immune function might be influenced by ...
... Identifying preterm infants at risk of life-threatening conditions ... life-threatening conditions that are clinically difficult to detect. These ... are present in the blood, and necrotizing enterocolitis, a ... now, Terrence Poon and colleagues, at the The Chinese ...
Cached Medicine News:Health News:Why are blacks more likely to die from cancer diagnosis? 2Health News:RSLSteeper announces pricing for new bionic hand 2Health News:Scientists Spot Gene Variants That Predict Longevity 2Health News:Scientists Spot Gene Variants That Predict Longevity 3Health News:Sex With Recent Smallpox Vaccine Recipient Can Lead to Illness 2Health News:Sex With Recent Smallpox Vaccine Recipient Can Lead to Illness 3Health News:Genetic regulator opens new avenues to AIDS, immune system research 2Health News:JCI online early table of contents: July 1, 2010 2Health News:JCI online early table of contents: July 1, 2010 3Health News:JCI online early table of contents: July 1, 2010 4Health News:JCI online early table of contents: July 1, 2010 5Health News:JCI online early table of contents: July 1, 2010 6Health News:JCI online early table of contents: July 1, 2010 7
The Olympus full range of laparoscopes includes a range of diameters and directions of view -12 mm HDTV compatible model as well as a choice of 10 mm, 5 mm full screen and 3 mm....
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
The Concept Plus also allows users to transfer large bottles, flasks and other equipment, quickly and efficiently. The front-loading interlock features class leading one touch operation and easy acce...
... and proven features of the Bugbox, but is ... system.The gas mixing module provides accurate control over ... dioxide (0% - 12% in 1% increments) and ... of the mix, with integral oxygen sensor and ...
Medicine Products: